EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK.
EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the traditional demo day, and will go beyond startups pitching to investors, instead presenting the ecosystem EyeFocus has built in eye-care innovation.

The conference will bring together thought leaders from across eye-care, innovation, and tech. The day will feature keynote talks, discussion panels, and short pitches from a broad range of the companies in the EyeFocus program, from startups to developed businesses.

The aim of the day is to share the built ecosystem, and the knowledge clustered around EyeFocus, and to promote innovation in eye-care. The day will be a mix of networking, education, and information for people working in eye-care, health tech, and startups.

EyeFocus Eye Care Innovation Conference is sponsored by Bayer, and has partnered with the world famous Royal National Institute for Blind People (RNIB), and Royal Academy of Engineering (RAENG) to bring thought leaders from across the eye-care spectrum together for a unique event in the centre of London.

For further information and to buy tickets, please visit:
https://www.eventbrite.com/e/eyefocus-conference-tickets-29612858858?aff=eHealthNews&afu=197085922377

About EyeFocus
EyeFocus is the world's first eye-care accelerator and innovation program. We run events around the world to bring together opinion leaders and practitioners in eye-care innovation to leave our ecosystem better connected, and to focus academics, innovators, and practitioners on thinking about how to create new products and solutions for people who are blind or visually impaired.

EyeFocus is a project of Newsquare Innovation. Newsquare develops programs to create connected ecosystems in healthcare innovation, accelerating early stage companies, and building bridges between academia, industry, entrepreneurs, and healthcare.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...